Literature DB >> 23649974

The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.

Juliano D Paccez1, Matjaz Vogelsang, M Iqbal Parker, Luiz F Zerbini.   

Abstract

The receptor tyrosine kinase Axl has been implicated in the malignancy of different types of cancer. Emerging evidence of Axl upregulation in numerous cancers, as well as reports demonstrating that its inhibition blocks tumor formation in animal models, highlight the importance of Axl as a new potential therapeutic target. Furthermore, recent data demonstrate that Axl plays a pivotal role in resistance to chemotherapeutic regimens. In this review we discuss the functions of Axl and its regulation and role in cancer development, resistance to therapy, and its importance as a potential drug target, focusing on acute myeloid leukemia, breast, prostate and non-small cell lung cancers.
© 2013 UICC.

Entities:  

Keywords:  Axl; cancer; cancer therapy; drug resistance; receptor tyrosine kinases

Mesh:

Substances:

Year:  2013        PMID: 23649974     DOI: 10.1002/ijc.28246

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  63 in total

1.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Authors:  Moshe Elkabets; Evangelos Pazarentzos; Dejan Juric; Qing Sheng; Raphael A Pelossof; Samuel Brook; Ana Oaknin Benzaken; Jordi Rodon; Natasha Morse; Jenny Jiacheng Yan; Manway Liu; Rita Das; Yan Chen; Angela Tam; Huiqin Wang; Jinsheng Liang; Joseph M Gurski; Darcy A Kerr; Rafael Rosell; Cristina Teixidó; Alan Huang; Ronald A Ghossein; Neal Rosen; Trever G Bivona; Maurizio Scaltriti; José Baselga
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma.

Authors:  Takehiko Shibata; David M Habiel; Ana L Coelho; Steven L Kunkel; Nicholas W Lukacs; Cory M Hogaboam
Journal:  J Immunol       Date:  2014-03-21       Impact factor: 5.422

3.  AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.

Authors:  Anna de Polo; Zhongling Luo; Casimiro Gerarduzzi; Xiang Chen; John B Little; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2017-04-01       Impact factor: 6.216

4.  Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis.

Authors:  Muhammad S Beg; Arjun Gupta; David Sher; Sadia Ali; Saad Khan; Ang Gao; Tyler Stewart; Chul Ahn; Jarett Berry; Eric M Mortensen
Journal:  Am J Clin Oncol       Date:  2018-08       Impact factor: 2.339

5.  Axl receptor tyrosine kinase expression in breast cancer.

Authors:  Timothy M D'Alfonso; Jeffrey Hannah; Zhengming Chen; Yifang Liu; Pengbo Zhou; Sandra J Shin
Journal:  J Clin Pathol       Date:  2014-06-05       Impact factor: 3.411

6.  How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.

Authors:  Marcin Kortylewski; Sergey Nechaev
Journal:  Mol Ther       Date:  2014-06       Impact factor: 11.454

7.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

8.  Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.

Authors:  Yanting Duan; Bo Hu; Chunxia Qiao; Longlong Luo; Xinying Li; Jing Wang; Hao Liu; Tingting Zhou; Beifen Shen; Ming Lv; Jiannan Feng
Journal:  Oncol Lett       Date:  2019-04-15       Impact factor: 2.967

9.  Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.

Authors:  Robert Torka; Kinga Pénzes; Simone Gusenbauer; Christine Baumann; István Szabadkai; Lászlȯ Őrfi; György Kéri; Axel Ullrich
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

10.  Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years.

Authors:  Gry S Haaland; Ragnhild S Falk; Oddbjørn Straume; James B Lorens
Journal:  JAMA Intern Med       Date:  2017-12-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.